| Autor: |
Ambrosio AM; Instituto Nacional de Enfermedades Virales Humanas Dr. J.I. Maiztegui, Monteagudo 2510, 2700 Pergamino, Provincia de Buenos Aires, Argentina. anaambrosio@yahoo.com.ar, Riera LM, Saavedra Mdel C, Sottosanti MJ |
| Jazyk: |
Spanish; Castilian |
| Zdroj: |
Medicina [Medicina (B Aires)] 2005; Vol. 65 (4), pp. 329-32. |
| Abstrakt: |
Candid #1 vaccine against Argentine Hemorrhagic Fever produced in USA versus lots of the same vaccine made in Argentina were compared in guinea pigs regarding safety, immunogenicity and protective efficacy against a challenge with pathogenic Junin virus. Lots No Exp 3, 7A and 8A of Argentine origin as well as lot TSI 5-1-92 from USA were inoculated in guinea pigs of 250-400 g in two consecutive assays. Ten animals inoculated with saline performed as normal controls in each experiment. Parameters studied were: a) temperature; b) body weight; c) neutralizing antibodies to Junin virus; d) response to viral challenge. Animals gained weight and remained normothermic up to the challenge. Guinea pigs that received Candid #1 from any manufacturer elicited neutralizing antibodies to Junin virus (titles from 40 to 81920) and survived to challenge whilst 8/10 animals died in each control group. Data presented demonstrated that Candid #1 vaccines from USA or Argentine manufacturers were equally safe, immunogenic and protective in guinea pigs. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
